Allspring Global Investments Holdings LLC Acquires 169,628 Shares of Phibro Animal Health Corporation $PAHC

Allspring Global Investments Holdings LLC boosted its stake in Phibro Animal Health Corporation (NASDAQ:PAHC) by 145.5% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 286,172 shares of the company’s stock after purchasing an additional 169,628 shares during the period. Allspring Global Investments Holdings LLC owned about 0.71% of Phibro Animal Health worth $15,671,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of PAHC. 1620 Investment Advisors Inc. raised its position in shares of Phibro Animal Health by 77.4% during the fourth quarter. 1620 Investment Advisors Inc. now owns 676 shares of the company’s stock worth $25,000 after acquiring an additional 295 shares during the last quarter. Farther Finance Advisors LLC boosted its holdings in Phibro Animal Health by 113.2% in the fourth quarter. Farther Finance Advisors LLC now owns 727 shares of the company’s stock valued at $27,000 after acquiring an additional 386 shares during the last quarter. Rothschild Investment LLC increased its position in Phibro Animal Health by 2,500.0% during the 4th quarter. Rothschild Investment LLC now owns 1,040 shares of the company’s stock valued at $39,000 after purchasing an additional 1,000 shares during the period. iSAM Funds UK Ltd acquired a new stake in Phibro Animal Health during the 3rd quarter valued at approximately $61,000. Finally, EverSource Wealth Advisors LLC raised its holdings in Phibro Animal Health by 7,671.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,720 shares of the company’s stock worth $69,000 after purchasing an additional 2,685 shares during the last quarter. 99.34% of the stock is owned by institutional investors.

Phibro Animal Health Trading Up 2.5%

Shares of Phibro Animal Health stock opened at $33.86 on Wednesday. The company has a debt-to-equity ratio of 1.97, a quick ratio of 1.26 and a current ratio of 3.17. Phibro Animal Health Corporation has a 52 week low of $25.58 and a 52 week high of $60.08. The stock has a 50 day moving average price of $32.53 and a two-hundred day moving average price of $43.37. The stock has a market capitalization of $1.37 billion, a PE ratio of 14.53, a price-to-earnings-growth ratio of 0.46 and a beta of 0.46.

Phibro Animal Health (NASDAQ:PAHC) last issued its earnings results on Wednesday, May 6th. The company reported $0.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.72 by $0.04. Phibro Animal Health had a return on equity of 37.14% and a net margin of 6.35%.The company had revenue of $383.54 million for the quarter, compared to analysts’ expectations of $367.02 million. Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. As a group, equities analysts anticipate that Phibro Animal Health Corporation will post 3.08 earnings per share for the current fiscal year.

Phibro Animal Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, June 24th. Stockholders of record on Wednesday, June 3rd were paid a $0.12 dividend. The ex-dividend date of this dividend was Wednesday, June 3rd. This represents a $0.48 annualized dividend and a dividend yield of 1.4%. Phibro Animal Health’s dividend payout ratio is 20.60%.

Analyst Upgrades and Downgrades

PAHC has been the topic of a number of recent analyst reports. Citigroup dropped their price target on shares of Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating on the stock in a research report on Thursday, May 14th. Wall Street Zen cut shares of Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Zacks Research downgraded Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 21st. Finally, Weiss Ratings lowered Phibro Animal Health from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, June 15th. One investment analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Phibro Animal Health currently has an average rating of “Hold” and an average price target of $42.50.

Insider Activity at Phibro Animal Health

In other news, CEO Jack Bendheim sold 4,528 shares of the firm’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $48.49, for a total value of $219,562.72. Following the transaction, the chief executive officer owned 56,152 shares in the company, valued at $2,722,810.48. This trade represents a 7.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 25,648 shares of company stock valued at $1,377,432 over the last three months. Corporate insiders own 50.13% of the company’s stock.

Phibro Animal Health Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.